Volume 10, Issue 1 (7-2012)                   IJRM 2012, 10(1): 59-66 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Karimi S, Yavarian M, Azinfar A, Rajaei M, Azizi Kootenaee M. Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population. IJRM. 2012; 10 (1) :59-66
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-248-en.html
1- Department of Obstetrics and Gynecology, Hormozgan Fertility and Infertility Research Center, Shariati Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2- Department of Human Molecular and Clinical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran
3- Department of Obstetrics and Gynecology, Hormozgan Fertility and Infertility Research Center, Shariati Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran , aazinfar@yahoo.com
Abstract:   (1930 Views)
Background: Role of genetic factors in etiology of preeclampsia is not confirmed yet.
Objective: Gene defect frequency varies in different geographic areas as well as ethnic groups. In this study, the role of factor V Leiden mutation in the pathogenesis of preeclampsia syndrome among the pregnant population of northern shore of Persian Gulf in Iran, were considered.
Materials and Methods: Between Jan. 2008 and Dec. 2009, in a nested case control study, pregnant women with preeclampsia (N=198) as cases and healthy (N=201) as controls were enrolled in the study. DNA were extracted from 10 CC peripheral blood and analyzed for presence of factor V Leiden mutation in these subjects. The maternal and neonatal outcomes of pregnancy according to the distribution of factor V Leiden were also compared among cases.
Results: In total, 17(8.6%) of cases and 2(1%) of controls showed the factor V Leiden mutation. The incidence of factor V Leiden was typically higher in preeclamptic women than control group (OR: 9.34 %95 CI: 2.12-41.01). There was no difference in incidence rate of preterm delivery< 37 weeks (OR: 1.23 %95 CI: 0.38-4.02), very early preterm delivery<32 weeks (OR: 1.00 %95 CI: 0.12-8.46), intra uterine fetal growth restriction (IUGR) (OR: 1.32 %95 CI: 0.15-11.30 ),and the rate of cesarean section (OR: 0.88 %95 CI: 0.29-2.62 ) among cases based on the prevalence of factor V Leiden mutation.
Conclusion: The pregnant women with factor V Leiden mutation are prone for preeclampsia syndrome during pregnancy, but this risk factor was not correlated to pregnancy complications in the studied women. 
Full-Text [PDF 170 kb]   (143 Downloads) |   |   Full-Text (HTML)  (91 Views)  
Type of Study: Original Article |

1. Irminger-Finger I, Jastrow N, Irion O. Preeclampsia: A danger growing in disguise. Int J Biochem Cell Biol 2008; 40: 1979-1983. [DOI:10.1016/j.biocel.2008.04.006]
2. Saadat M, Nejad SM, Habibi G, Sheikhvatan M. Maternal and neonatal outcomes in women with preeclampsia. Taiwan J Obstet Gynecol 2007; 46: 255-259. [DOI:10.1016/S1028-4559(08)60029-7]
3. Dildy GA 3rd, Belfort MA, Smulian JC. Preeclampsia recurrence and prevention. Semin Perinatol 2007; 31: 135-141. [DOI:10.1053/j.semperi.2007.03.005]
4. Bolte AC, van Geijn HP, Dekker GA. Management and monitoring of severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001; 96: 8-20. [DOI:10.1016/S0301-2115(00)00383-3]
5. Gaugler-Senden IP, Huijssoon AG, Visser W, Steegers EA, de Groot CJ. Maternal and perinatal outcome of preeclampsia with an onset before 24 weeks' gestation: Audit in a tertiary referral center. Eur J Obstet Gynecol Reprod Biol 2006; 128: 216-221. [DOI:10.1016/j.ejogrb.2005.11.011]
6. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97: 533-538.
7. Lachmeijer AM, Dekker GA, Pals G, Aarnoudse JG, ten Kate LP, Arngrímsson R. Searching for preeclampsia genes: The current position. Eur J Obstet Gynecol Reprod Biol 2002; 105: 94-113. [DOI:10.1016/S0301-2115(02)00208-7]
8. Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res 2010; 125: 119-123. [DOI:10.1016/j.thromres.2009.11.003]
9. Paidas MJ, Ku D-HW, Langhoff-Roos J, Arkel YS. Inherited thrombophilias and adverse pregnancy outcome: Screening and management. Semin Perinatol 2005; 29: 150-163. [DOI:10.1053/j.semperi.2005.05.008]
10. Hiltunen LM, Laivuori H, Rautanen A, Kaaja R, Kere J, Krusius T, et al. Blood group ab and factor V Leiden as risk factors for pre-eclampsia: A population-based nested case-control study. Thromb Res 2009; 124: 167-173. [DOI:10.1016/j.thromres.2008.11.012]
11. Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200: 41-45. [DOI:10.1016/j.ajog.2008.07.032]
12. Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005; 192: 694-708. [DOI:10.1016/j.ajog.2004.09.011]
13. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications and adverse outcomes: The hordaland homocysteine study. QJM 2006; 99: 289-298. [DOI:10.1093/qjmed/hcl040]
14. Mtiraoui N, Borgi L, Hizem S, Nsiri B, Finan RR, Gris J-C, et al. Prevalence of antiphospholipid antibodies, factor V g1691a (Leiden) and prothrombin g20210a mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2005; 119: 164-170. [DOI:10.1016/j.ejogrb.2004.07.003]
15. Hiltunen LM, Laivuori H, Rautanen A, Kaaja R, Kere J, Krusius T, et al. Factor V Leiden as risk factor for unexplained stillbirth- a population-based nested case-control study. Thromb Res 2010; 125: 505-510. [DOI:10.1016/j.thromres.2009.09.016]
16. Glueck CJ, Gogenini S, Munjal J, Tracy T, Pranikoff J, Wang P. Factor V Leiden mutation: A treatable etiology for sporadic and recurrent pregnancy loss. Fertil Steril 2008; 89: 410-416. [DOI:10.1016/j.fertnstert.2007.03.011]
17. Hussein AS, Darwish H, Shelbayeh K. Association between factor V Leiden mutation and poor pregnancy outcomes among palestinian women. Thromb Res 2010; 126: 78-82. [DOI:10.1016/j.thromres.2010.04.017]
18. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185: 153-157. [DOI:10.1067/mob.2001.114691]
19. Salomon O, Seligsohn U, Steinberg DM, Zalel Y, Lerner A, Rosenberg N, et al. The common prothrombotic factors in nulliparous women do not compromise blood flow in the feto-maternal circulation and are not associated with preeclampsia or intrauterine growth restriction. Am J Obstet Gynecol 2004; 191: 2002-2009. [DOI:10.1016/j.ajog.2004.07.053]
20. Von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or hellp-syndrome. Thromb Res 2000; 100: 363-365. [DOI:10.1016/S0049-3848(00)00312-1]
21. Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ, Peraud PJ, et al. Genetic susceptibility to preeclampsia: Roles of cytosine-to-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine -synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001; 184: 1211-1217. [DOI:10.1067/mob.2001.110411]
22. Nath CA, Ananth CV, DeMarco C, Vintzileos AM, New Jersey-Placental Abruption Study Investigators. Low birthweight in relation to placental abruption and maternal thrombophilia status. Am J Obstet Gynecol 2008; 198: 291-295. [DOI:10.1016/j.ajog.2007.09.011]
23. ACOG Committee on Obstetrics Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, january 2002. American college of obstetricians and gynecologists. Int J Gynaecol Obstet 2002; 77: 67-75.
24. Lucotte G, Mercier G. Population genetics of factor V leiden in europe. Blood Cells Mol Dis 2001; 27: 362-367. [DOI:10.1006/bcmd.2001.0388]
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215. [DOI:10.1093/nar/16.3.1215]
26. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence Prothrombin G20210A was reported to be more common of a mutation in the factor V gene within the UK population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-222. [DOI:10.1111/j.1365-2141.1994.tb05005.x]
27. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210a, methylenetetrahydrofolate reductase 677t, and population genetics. Mol Genet Metab 2005; 86: 91-99. [DOI:10.1016/j.ymgme.2005.04.002]
28. Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT. Racial differences in the prevalence of factor V Leiden mutation among patients on chronic warfarin therapy. Blood Cells Mol Dis 2006; 37: 100-106. [DOI:10.1016/j.bcmd.2006.06.003]
29. Kobashi G, Yamada H, Asano T, Nagano S, Hata A, Kishi R, et al. The factor V Leiden mutation is not a common cause of pregnancy-induced hypertension in japan. Semin Thromb Hemost 1999; 25: 487-489. [DOI:10.1055/s-2007-994955]
30. Rahimi Z, Vaisi-Raygani A, Mozafari H, Kharrazi H, Rezaei M, Nagel RL .Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolysis 2008; 25: 280-283. [DOI:10.1007/s11239-007-0052-6]
31. Karimi M, Panahandeh Shahraki G, Yavarian M, Afrasiabi A, Dehbozorgian J, Bordbar M, et al. Frequency of factor V Leiden and Prothrombin Polymorphism in South of Iran. Iran J Med Sci 2009; 34: 137-140.
32. Dashti AA, Jadaon MM. Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals. Mol Biol Rep 2011; 38: 3623-3628. [DOI:10.1007/s11033-010-0474-7]
33. Sadat Hosseini M, Gharehkhani P, Sadeghi M. Association of inherited thrombophilia and antiphospholipid syndrome with sever preeclampsia. Iran J Reprod Med 2007; 5: 183-186.
34. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-905. [DOI:10.1016/S0002-9378(96)80022-6]
35. Dávalos IP, Moran MC, Martínez-Abundis E, González-Ortiz M, Flores-Martínez SE, Machorro V, et al. Methylenetetrahydrofolate reductase c677t polymorphism and factor V Leiden variant in mexican women with preeclampsia/eclampsia. Blood Cells Mol Dis 2005; 35: 66-69. [DOI:10.1016/j.bcmd.2005.03.008]
36. Prasmusinto D, Skrablin S, Fimmers R, van der Ven K. Ethnic differences in the association of factor V Leiden mutation and the c677t methylenetetrahydrofolate reductase gene polymorphism with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2004; 112: 162-169. [DOI:10.1016/S0301-2115(03)00314-2]
37. Dudding T, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: A genetic association study and meta-analysis. J Thromb Haemost 2008; 6: 1869-1875. [DOI:10.1111/j.1538-7836.2008.03134.x]
38. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: A meta-analysis. J Hypertens 2003; 21: 1221-1228. [DOI:10.1097/00004872-200307000-00002]
39. Dalmáz CA, Santos KG, Botton MR, Tedoldi CL, Roisenberg I. Relationship between polymorphisms in thrombophilic genes and preeclampsia in a brazilian population. Blood Cells Mol Dis 2006; 37: 107-110. [DOI:10.1016/j.bcmd.2006.07.005]
40. Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J Jr, et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: The montreal preeclampsia study. Am J Obstet Gynecol 2009; 200: 151-159. [DOI:10.1016/j.ajog.2008.09.023]
41. Zahed LF, Rayes RF, Mahfouz RA, Taher AT, Maarouf HH, Nassar AH. Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in lebanon. Am J Obstet Gynecol 2006; 195: 1114-1118. [DOI:10.1016/j.ajog.2006.06.082]
42. Wang Y, Walli AK, Schulze A, Blessing F, Fraunberger P, Thaler C, et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus and Apher Sci 2006; 35: 103-110. [DOI:10.1016/j.transci.2006.05.010]

Send email to the article author

© 2021 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb